The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma

Modern Pathology

Volumn 25, Issue 8, 2012, Pages 1098-1105

  Yildiz Aktas, Isil Z ^a   Dabbs, David J ^a   Bhargava, Rohit ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

breast carcinoma; cold ischemic time; ER PR HER2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; CLINICAL ARTICLE; COLD ISCHEMIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASTECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; ROOM TEMPERATURE; TISSUE FIXATION; TUMOR BIOPSY;

BIOPSY, LARGE-CORE NEEDLE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COLD ISCHEMIA; CRYOPRESERVATION; FEMALE; FIXATIVES; HUMANS; IMMUNOHISTOCHEMISTRY; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; STAINING AND LABELING; TIME FACTORS; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84864558789     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.59     Document Type: Article

References (27)

1. Liu S, Chia SK, Mehl E, et al. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat 2010;119:53-61.
2. Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 2004;17:1545-1554.
3. Fisher B, Redmond C, Brown A, et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 1981;305:1-6.
4. Fisher B, Redmond C, Brown A, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in breast cancer. J Clin Oncol 1983;1:227-241.
5. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-5312.
6. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-978.
7. Early Breast Cancer Trialists' Collaborative Group E. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;365:1687-1717.
8. Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogen progesterone receptor expression human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, alone or in combination trial. J Clin Oncol 2008;26:1059-1065.
9. Press MF, Pike MC, Chazin VR, et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-4970.
10. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-2904.
11. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334-2356.
12. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the Her-2/neu proto-oncogene in human breast ovarian cancer. Science 1989;244:707-712.
13. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43.
14. Bast RCJ, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-1878.
15. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen progesterone receptors in breast cancer. Arch Pathol Lab Med 2010;134:e48-e72.
16. Gown AM. Unmasking the mysteries of antigen or epitope retrieval formalin fixation. Am J Clin Pathol 2004;121:172-174.
17. Nenci I, Beccati MD, Piffanelli A, et al. Detection dynamic localisation of estradiol-receptor complexes in intact target cells by immunofluorescence technique. J Steroid Biochem 1976;7:505-510.
18. Diaz LK, Sneige N. Estrogen receptor analysis for breast cancer: current issues keys to increasing testing accuracy. Adv Anat Pathol 2005;12:10-19.
19. Yaziji H, Taylor CR, Goldstein NS, et al. Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol 2008;16:513-520.
20. Goldstein NS, Ferkowicz M, Odish E, et al. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 2003;120:86-92.
21. Flanagan MB, Dabbs DJ, Brufsky AM, et al. Histopathologic variables predict oncotype DX recurrence score. Mod Pathol 2008;21:1255-1261.
22. McCarty Jr KS, Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of biochemical immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985;109: 716-721.
23. Uy GB, Laudico AV, Carnate Jr JM, et al. Breast cancer hormone receptor assay results of core needle biopsy modified radical mastectomy specimens from the same patients. Clin Breast Cancer 2010;10: 154-159.
24. Khoury T, Sait S, Hwang H, et al. Delay to formalin fixation effect on breast biomarkers. Mod Pathol 2009;22:1457-1467.
25. Apple S, Pucci R, Lowe AC, et al. The effect of delay in fixation different fixatives, duration of fixation in estrogen progesterone receptor results in breast carcinoma. Am J Clin Pathol 2011;135:592-598.
26. Moatamed NA, Nanjangud G, Pucci R, et al. Effect of ischemic time fixation time, fixative type on HER2/neu immunohistochemical fluorescence in situ hybridization results in breast cancer. Am J Clin Pathol 2011;136:754-761.
27. Qiu J, Kulkarni S, Chandrasekhar R, et al. Effect of delayed formalin fixation on estrogen progesterone receptors in breast cancer: a study of three different clones. Am J Clin Pathol 2010;134:813-819.